Latest news

• AbbVie’s upadacitinib aces phase III trial

  The drug is vying to become the third drug in the class after Pfizer’s Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib), which was turned down by the FDA at

• Lilly drops Hanmi-partnered arthritis drug

  Lilly’s willingness to take a risk on continuing development of the drug in other indications may be cut now that it has won approval for JAK inhibitor Olumiant (baricitinib) for

• AbbVie reports more solid data for would-be psoriasis blockbuster

  Upadacitinib is vying to become the third drug in the class after Pfizer’s Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib) as a rheumatoid arthritis treatment, reporting encouraging phase III

• J&J takes option on Theravance’s JAK drug in $1bn deal

  Lilly becoming the first direct competitor last year when it bagged EU approval for Olumiant (which has been delayed in the US).

• AbbVie’s JAK inhibitor upadacitinib clears another phase III trial

  Thrombosis fears caused it to reject Olumiant, forcing Lilly to re-file the drug earlier this year, although it has been approved in Europe. ... Olumiant has been pegged back by the FDA rejection and made just over $22m in the same period after getting